Chiara Fornara1, Milena Furione2, Daniele Lilleri1, Ilaria Cane1, M Grazia Revello3, Maurizio Zavattoni2, Giuseppe Gerna4. 1. Laboratori Sperimentali di Ricerca, Area Trapiantologica, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy. 2. Struttura Semplice Virologia Molecolare, Struttura Complessa Microbiologia e Virologia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy. 3. Struttura Complessa Ostetricia e Ginecologia, Università degli Studi di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy. 4. Laboratori Sperimentali di Ricerca, Area Trapiantologica, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy. Electronic address: g.gerna@smatteo.pv.it.
Abstract
BACKGROUND: Human cytomegalovirus infections are mostly asymptomatic in infants and young children, while they are often associated with overt clinical symptoms in adults. OBJECTIVES: To verify whether the antibody response to HCMV is more potent in symptomatic non-pregnant adults as compared to asymptomatic/paucisymptomatic pregnant women. STUDY DESIGN: Overall, 36 consecutive pregnant women with primary HCMV infection were compared with 10 consecutive symptomatic non-pregnant subjects with primary HCMV infection and overt clinical symptoms. Levels of IgG antibody responses to HCMV-infected cell lysate and the pentamer gH/gL/pUL128L, gH/gL and gB HCMV glycoprotein complexes as well as neutralizing antibodies preventing infection of epithelial cells (ARPE-19) and human embryonic lung fibroblast (HELF) cells were compared at intervals of 1-30, 31-60, 61-90, 91-180 and 181-360 days after onset of infection. In parallel, viral load was quantified by real-time PCR. RESULTS: In symptomatic non-pregnant subjects, the IgG responses to HCMV lysate as well as to gH/gL and ARPE-19 neutralizing antibodies were significantly higher from 31 to 60 through 180 days after infection onset. In the same patients, the IgG antibody responses to the pentamer and HELF-neutralizing antibody were significantly higher starting 90 days post-infection. CONCLUSIONS: The presence of overt clinical symptoms is associated with a significantly higher antibody response (concomitantly with a higher viral load) in non-pregnant subjects with symptomatic primary HCMV infection as compared to pregnant women with paucisymptomatic/ asymptomatic primary infection (and lower viral load).
BACKGROUND:Humancytomegalovirus infections are mostly asymptomatic in infants and young children, while they are often associated with overt clinical symptoms in adults. OBJECTIVES: To verify whether the antibody response to HCMV is more potent in symptomatic non-pregnant adults as compared to asymptomatic/paucisymptomatic pregnant women. STUDY DESIGN: Overall, 36 consecutive pregnant women with primary HCMV infection were compared with 10 consecutive symptomatic non-pregnant subjects with primary HCMV infection and overt clinical symptoms. Levels of IgG antibody responses to HCMV-infected cell lysate and the pentamer gH/gL/pUL128L, gH/gL and gB HCMV glycoprotein complexes as well as neutralizing antibodies preventing infection of epithelial cells (ARPE-19) and humanembryonic lung fibroblast (HELF) cells were compared at intervals of 1-30, 31-60, 61-90, 91-180 and 181-360 days after onset of infection. In parallel, viral load was quantified by real-time PCR. RESULTS: In symptomatic non-pregnant subjects, the IgG responses to HCMV lysate as well as to gH/gL and ARPE-19 neutralizing antibodies were significantly higher from 31 to 60 through 180 days after infection onset. In the same patients, the IgG antibody responses to the pentamer and HELF-neutralizing antibody were significantly higher starting 90 days post-infection. CONCLUSIONS: The presence of overt clinical symptoms is associated with a significantly higher antibody response (concomitantly with a higher viral load) in non-pregnant subjects with symptomatic primary HCMV infection as compared to pregnant women with paucisymptomatic/ asymptomatic primary infection (and lower viral load).
Authors: Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar Journal: J Infect Dis Date: 2020-03-05 Impact factor: 5.226
Authors: Yujuan Yue; W L William Chang; Julia Li; Nancy Nguyen; Kimberli A Schmidt; Philip R Dormitzer; Xinzhen Yang; Peter A Barry Journal: J Virol Date: 2021-11-17 Impact factor: 6.549
Authors: Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans Journal: Clin Microbiol Rev Date: 2019-12-11 Impact factor: 26.132
Authors: Isa Murrell; Carmen Bedford; Kristin Ladell; Kelly L Miners; David A Price; Peter Tomasec; Gavin W G Wilkinson; Richard J Stanton Journal: Proc Natl Acad Sci U S A Date: 2017-05-22 Impact factor: 12.779
Authors: Virginia-Maria Vlahava; Isa Murrell; Lihui Zhuang; Rebecca J Aicheler; Eleanor Lim; Kelly L Miners; Kristin Ladell; Nicolás M Suárez; David A Price; Andrew J Davison; Gavin Wg Wilkinson; Mark R Wills; Michael P Weekes; Eddie Cy Wang; Richard J Stanton Journal: J Clin Invest Date: 2021-02-15 Impact factor: 14.808
Authors: Rémi N Charrel; Isabelle Leparc-Goffart; Suzan Pas; Xavier de Lamballerie; Marion Koopmans; Chantal Reusken Journal: Bull World Health Organ Date: 2016-08-01 Impact factor: 9.408